Dr. Reddy's Laboratories has commenced reorganisation of its research and development (R&D) business for ensuring a greater impact on the near-term earnings without losing focus on the long-term interests of the company.
DRL Chairman K. Anji Reddy said the company's R&D efforts were scaling up and moving in the right direction. Work was under way on 20 products that include new chemical entities (NCE), multi-drug combinations and novel differentiated formulations. The foremost in the NCE programme was the CETP inhibitor which recently moved to Phase-2.
Addressing the company's 27th annual meeting here on Thursday, Dr. Reddy said the company's immediate goal was to make its branded generics arm a billion dollar business.
The key drivers towards this end would be India and Russia, the two large emerging markets where DRL had a strong presence.
